March 14-16, 2016 – San Antonio, TX USA. INCELL is a Sponsor of the 2016 national Parenteral Drug Association (PDA) meeting. INCELL will have a trade show booth with manufacturing and project managers on site to discuss manufacturing sterile fill and other products. INCELL scientists, Dr. Mary Pat Moyer, Vanessa Ramirez and George Plasko will participate in the 3-day event, discussions, networking and business development.
April 7-9, 2016 – Austin, TX USA. Dr. Mary Pat Moyer, INCELL CEO and Chief Science Officer, is an invited member of the National Visiting Committee for the National Science Foundation (NSF)-supported Bio-Link Regional Center and biotechnology training program at Austin Community College . sites.austincc.edu/biotech nsf.gov/awards/about.jsp
January 21-22, 2016 – Corpus Christi, TX USA. Dr. Mary Pat Moyer, INCELL CEO and Chief Science Officer, participated as an invited member of the National Visiting Committee for review of the Del Mar College “ReVision Project: Revising Science Education with Vision” supported with funding from the National Science Foundation (NSF) Advanced Technology Education program. INCELL is a corporate advisor and provides an on-the-job training site for students in that program as well as the Biotechnology Certificate Program.
https://www.delmar.edu/Biotechnology/biotechnology.aspx
February 23, 2016-San Antonio, TX USA. Dr. Mary Pat Moyer, INCELL CEO and Chief Science Officer, and UTHSCSA Professor gave an invited presentation “Managing Integrity as a Core Value in a Biomedical Company” at the University of Texas Health Science Center at San Antonio “Spotlight on Research Integrity” Lecture Series. More Information…
February 24, 2016-San Antonio, TX USA. READY TO GROW! INCELL received a new Certificate of Occupancy from the City of San Antonio for its adjacent building expansion space of about 10,000 additional square feet at 12746 Cimarron Path, Suite 103. Updating and renovations will commence March 1, 2016. INCELL affiliated companies 4RMED (focused on clinical trials) and TEKSA Innovations Corp. (a business incubator company) will be co-located at the new site.
January 24-27, 2016 – Washington DC, USA. INCELL was a corporate Sponsor of the 2016 Phacilitate Cell and Gene Therapy World Conference and Bio-Leaders Forum. www.phacilitate.co.uk
However, INCELL could not participate and Dr. Moyer was not able to give her panel presentation on “strategic and technological steps in manufacturing” when all flights from San Antonio into Washington DC were canceled due to unexpected historic blizzard conditions! www.weather.com
January 12, 2016 – San Antonio, TX USA. INCELL hosted international visitors for presentation, tour and discussions. INCELL was selected by Global Strategic Partnerships as a visit site representing a “best-in-class, organically grown” US-based life sciences company for the Innovation, Investment and Economic Development Program for 32 international Bentley University faculty and MBA students. The 2016 visitors were from many countries: Bulgaria, Egypt, India, Nigeria, Peru, Philippines, Poland, Romania, Russian Federation, Saudi Arabia, Serbia, Spain, Venezuela, and the United States.
www.bentley.edu/graduate/mba-programs/bmba/student-profile
April 15, 2016 – Dallas TX, USA. The FDA Medical Device Industry Coalition (FMDIC) is sponsoring its 2016 Big Event on the topic “Quality System Survival: Success Strategies for P&PC/CAPA.” fmdic.org/big-event-2016/ Dr. Mary Pat Moyer, FMDIC Member and INCELL CEO/CSO has been involved in the meeting planning and organization. Dr. Moyer and Lynn Miller, INCELL Quality Manager and FMDIC Member Alternate, will actively participate in the all-day public meeting.
September 12-13, 2016 – Washington DC, USA. Dr. Mary Pat Moyer, INCELL CEO and Chief Science Officer, has been selected to speak in Session 1 at the US Food and Drug Administration, Center for Biologics Evaluation and Research (CBER), Public Hearing on Draft Guidances Relating to the Regulation of Human Cells, Tissues or Cellular or Tissue-Based Products.
March 7, 2016 – San Antonio, TX USA. The Leadership Texas Class of 2016 has selected Dr. Mary Pat Moyer to be their honored guest at a recognition dinner as a “Luminary Woman of San Antonio.” Leadership Texas is highly competitive and the longest-running women’s leadership development program in the US. It is designed specifically to help women learn about critical issues outside of their own industries and spheres of influence. Dr. Moyer is a graduate of the class of 1992, and the experiences with her Leadership Texas class had a positive impact on her decision to found INCELL as a new biotechnology company in 1993. Leadership Women: Proudly presenting Leadership Texas since 1983. www.leadership-women.org
General Description
Table 1 shows media designations and supplement options. M3ä Base Medium is a proprietary formula that is a serum-free, highly enriched liquid culture medium for human stem cells and other progenitor and fastidious cell types. It is also useful for culture of animal-derived stem and progenitor cells, tumor cells, and tissues. It is the M3ä Base Medium to which serum, plasma, or other factors may be added to meet the needs of the individual cell-type. The M3™ base medium is used to make the M3™ family of serum-supplemented cell culture media. This includes M3:10™ which is the same as M3ä Base Medium supplemented with 10% v/v fetal bovine serum (FBS). M3ä Base is provided to international or other clients who need or want control over their sources of serum, and as the base medium to optimize FBS and other supplements for specific cell types or tissues (Table 2).
The extended M3™ media family includes M3:BaseA™, M3:BaseAC™, M3:BaseF™, M3:BaseFC™, M3:10A™ and M3:10AC™. Media suffix designations of “F”, “A” and “C” refer, respectively, to indicate Free of antibiotics, Antibiotic mixture (Gentamicin, Clindamycin and Amphotericin) and Clear (no phenol red). M3D™ (M3DEF) is the chemically defined solution of salts, sugars, amino acids, and buffers to which the growth supplements are added to make M3™ Base media. M3™ media are generally available in 100 mL and 500 mL volume sizes, but custom orders can be made for other sizes. SMX™ is available in a 25 mL volume size. M3:D™ (M3DEF) and the same formula without phenol red, i.e., M3:DC™ (M3DEC), are the chemically defined platform solution of salts, sugars, amino acids, and buffers to which the growth factors and other supplements are added to make the M3™ Base medium formula. M3:D™ or M3:DC™ are commonly used as a “control”, “holding” or “shift-down” media in studies where M3™ media are being used for growth or in vitro testing, and a control group requires absence of growth stimulating factors.
